KIT and neoplasm: For KIT and PDGF-a molecular mutations, analysis is strongly encouraged to be performed in cases with failure to imatinib mesylate therapy response, incomplete tumor resection, or metastasis especially for patients diagnosed with a high-risk group pathology.